Overview

A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC

Status:
Recruiting
Trial end date:
2022-08-27
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety of lenvatinib in HCC.
Phase:
Phase 4
Details
Lead Sponsor:
Eisai Pharmaceuticals India Pvt. Ltd
Treatments:
Lenvatinib